29 A Real-World Exploratory Analysis to Identify Disparities in Breast Cancer Tumor Biopsy Practice at Community Oncology Clinics in the United States

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 77

29 A Real-World Exploratory Analysis to Identify Disparities in Breast Cancer Tumor Biopsy Practice at Community Oncology Clinics in the United States

29 A Real-World Exploratory Analysis to Identify Disparities in Breast Cancer Tumor Biopsy Practice at Community Oncology Clinics in the United States

Background/Significance

The National Comprehensive Cancer Network (NCCN) guidelines recommend that all breast cancer patients have tumor phenotyping performed for estrogen receptor, progesterone receptor, and HER2 at the time of diagnosis. If patients experience recurrent disease or progression, an additional biopsy should be considered. This study evaluated metastatic breast cancer patients treated at community oncology practice sites across the US to measure the frequency, timing, regional variations, and predictors of repeat biopsies over the course of disease.

Materials and Methods

A weighted random sample of 911 metastatic breast cancer patients were selected from 15 practices within the ONCare Alliance cancer network. Data collection consisted of patient demographics, disease, and clinical characteristics at metastatic breast cancer diagnosis. Biopsy-related data collection included the total number performed over the course of disease, types of biopsies, and overall findings. Negative binomial regression with an adjustment for disease duration was used to identify factors associated with overall biopsy frequency.

Results

42.2% of patients have prior diagnosis of early-stage disease (ie, stage 0 to IIIC), and 57.8% were diagnosed de novo metastatic breast cancer. Performance status and disease-related parameters at metastatic breast cancer diagnosis were similar between the 2 groups. The mean number of biopsies in patients initially diagnosed with early-stage disease was 3.9 (95% CI, 3.7-4.0) compared with 2.2 (95% CI, 2.1-2.3) in the de novo metastatic breast cancer patient group (P <.001). Significant predictors of fewer biopsies included de novo metastatic breast cancer at diagnosis (risk ratio (RR), 0.76; P <.001), non-Black and non-Asian minorities (RR, 0.80; P <.001), a longer time to metastatic disease (RR, 0.93; P <.001), and poor performance status. There was substantial regional variation, with the Midwest having significantly higher mean biopsies per patient than all other regions (P <.001). Patients with HER2 immunohistochemistry ≥ 1+ were also 42% less likely to receive a second biopsy (OR, 0.58; P = .016).

Conclusion

After adjusting for disease duration, repeat biopsies at disease progression are not performed on a substantial proportion of patients, particularly those with de novo metastatic breast cancer or HER2 immunohistochemistry ≥ 1+. Potential disparities in access to repeat biopsies were also identified in non-Black and non-Asian minorities. This exploratory analysis may show the significance of biopsy guideline–concordant care initiatives in the community oncology setting.

Articles in this issue

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
Recent Videos
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Related Content